entertainment -WSS

entertainment

author：focus 2025-09-28 23:49:51 - browse：735

A few years ago, Vijay Pande, then a professor at Stanford who was using computer science to understand biology, was deciding whether to leave full-time academic work to become a venture capitalist. He turned to Andrew Ng, another Stanford professor who had joined Google Brain and later the Chinese search firm Baidu.

“The things that we dreamed about five or 10 years ago were happening now,” Pande recalled Ng telling him. “The question was, do you want to be a part of it? Or do you want to write another paper?”

Pande decided to become a venture capitalist. The result, he told an audience at a STAT event in San Francisco last week, is that, whereas he managed about $1 million to $2 million in research as a top academic, he now works at the fabled Silicon Valley firm Andreessen Horowitz, which invests $100 million a year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Amylyx ALS drug fails large clinical trial

WSS

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

What it’s like to watch children die of measles

BioAge raises $170M for combination therapy with Zepbound

Biden report: The neurospychology of memory and aging

Industry veterans launch new biotech VC with $310M

The dental labor crisis is a moment of opportunity

focus

entertainment

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Gilead might be held responsible for not developing a drug

Guidelines to prevent youth baseball injuries need more muscle

Change Healthcare cyberattack prompts Medicare loan program

How one medical school became remarkably diverse

PhRMA lawsuit over Medicare drug price negotiation tossed

Drug repurposing or repositioning? The language matters

Just how do doctors, lawmakers, and the public define abortion?

Apple is now the first public company to be valued at $3 trillion

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

hotspot

A deep dive into Applied Therapeutics’ data, and questions on Cassava

First medicine developed to treat MASH expected to be approved soon

IVF, abortion rights issues kick off Biden’s State of the Union

A disappointing year of Humira biosimilars

To avoid data mishandling cases, universities eye AI and other tools

To avoid data mishandling cases, universities eye AI and other tools

Wikipedia

focus

hotspot

knowledge